Suppr超能文献

膳食表没食子儿没食子酸酯补充剂用于治疗肥胖症和非酒精性脂肪性肝病的安全性和有效性:最新进展

The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates.

作者信息

Yan Ruike, Cao Yanli

机构信息

Department of Endocrinology and Metabolism, Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.

出版信息

Biomedicines. 2025 Jan 15;13(1):206. doi: 10.3390/biomedicines13010206.

Abstract

Epigallocatechin gallate (EGCG) is the predominant bioactive catechin in green tea, and it has been ascribed a range of beneficial health effects. Current increases in obesity and non-alcoholic fatty liver disease (NAFLD) rates represent a persistent and burdensome threat to global public health. While many clinical studies have demonstrated that EGCG is associated with positive effects on various health parameters, including metabolic biomarkers, waist circumference, and body weight when consumed by individuals affected by obesity and NAFLD, there are also some reports suggesting that it may entail some degree of hepatotoxicity. The present review provides a comprehensive summary of the extant clinical findings pertaining to the safety and effectiveness of EGCG in managing obesity and NAFLD, with a particular focus on how treatment duration and dose level affect the bioactivity of this compound.

摘要

表没食子儿没食子酸酯(EGCG)是绿茶中主要的生物活性儿茶素,人们认为它对健康有一系列有益影响。目前肥胖率和非酒精性脂肪性肝病(NAFLD)发病率的上升对全球公共卫生构成了持续且沉重的威胁。虽然许多临床研究表明,肥胖和NAFLD患者摄入EGCG后,它对包括代谢生物标志物、腰围和体重在内的各种健康参数有积极影响,但也有一些报告表明它可能有一定程度的肝毒性。本综述全面总结了关于EGCG在治疗肥胖和NAFLD方面的安全性和有效性的现有临床研究结果,特别关注治疗持续时间和剂量水平如何影响该化合物的生物活性。

相似文献

7
Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation.
Biochem Biophys Res Commun. 2024 Nov 19;734:150424. doi: 10.1016/j.bbrc.2024.150424. Epub 2024 Jul 18.
8
Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.
Mol Nutr Food Res. 2018 Jan;62(1). doi: 10.1002/mnfr.201700483. Epub 2017 Oct 12.

本文引用的文献

5
EGCG-NPs inhibition HO-1-mediated reprogram iron metabolism against ferroptosis after subarachnoid hemorrhage.
Redox Biol. 2024 Apr;70:103075. doi: 10.1016/j.redox.2024.103075. Epub 2024 Feb 11.
6
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
7
Prenatal EGCG consumption impacts hepatic glycogen synthesis and lipid metabolism in adult mice.
Int J Biol Macromol. 2024 Mar;260(Pt 1):129491. doi: 10.1016/j.ijbiomac.2024.129491. Epub 2024 Jan 14.
8
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):46-56. doi: 10.1038/s41575-023-00846-4. Epub 2023 Oct 5.
9
Obesity-induced and weight-loss-induced physiological factors affecting weight regain.
Nat Rev Endocrinol. 2023 Nov;19(11):655-670. doi: 10.1038/s41574-023-00887-4. Epub 2023 Sep 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验